AKT1 and non-small cell lung carcinoma: Associated with PI3K/Akt and Ras/Raf/MAPK, which downstream signaling pathways for EGFR, P‐MAPK and P‐Akt have been reported to evaluate the efficacy of gefitinib in patients with advanced NSCLC.115